Zafgen Inc

Larimar Therapeutics is a clinical-stage biotechnology company based in Boston, MA, dedicated to developing treatments for complex rare diseases. The company's lead product candidate, nomlabofusp, is currently undergoing evaluation in a Phase 2 clinical program aimed at treating Friedreich's ataxia, a rare genetic disorder.

Utilizing a proprietary intracellular delivery platform, Larimar Therapeutics aims to deliver proteins and other molecules directly into cells to address deficiencies associated with various rare diseases. The company plans to expand its pipeline by designing additional fusion proteins targeting other rare diseases characterized by intracellular protein deficiencies.

Generated from the website